{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:03Z","timestamp":1793745303413,"version":"4.6.1"},"reference-count":59,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In this study, we present the design, implementation, and successful use of digital droplet PCR (ddPCR) for the monitoring of chimeric antigen receptor T-cell (CAR-T) expansion in patients with B-cell malignancies treated with different CAR-T products at our clinical center. Initially, we designed a specific and highly sensitive ddPCR assay targeting the junction between the 4-1BB and CD3\u03b6 domains of tisa-cel, normalized with RPP30, and validated it using blood samples from the first tisa-cel-treated patient in Switzerland. We further compared this assay with a published qPCR (quantitative real-time PCR) design. Both assays showed reliable quantification of CAR-T copies down to 20 copies\/\u00b5g DNA. The reproducibility and precision were confirmed through extensive testing and inter-laboratory comparisons. With the introduction of other CAR-T products, we also developed a corresponding ddPCR assay targeting axi-cel and brexu-cel, demonstrating high specificity and sensitivity with a limit of detection of 20 copies\/\u00b5g DNA. These assays are suitable for CAR-T copy number quantification across multiple sample types, including peripheral blood, bone marrow, and lymph node biopsy material, showing robust performance and indicating the presence of CAR-T cells not only in the blood but also in target tissues. Longitudinal monitoring of CAR-T cell kinetics in 141 patients treated with tisa-cel, axi-cel, or brexu-cel revealed significant expansion and long-term persistence. Peak expansion correlated with clinical outcomes and adverse effects, as is now well known. Additionally, we quantified the CAR-T mRNA expression, showing a high correlation with DNA copy numbers and confirming active transgene expression. Our results highlight the quality of ddPCR for CAR-T monitoring, providing a sensitive, precise, and reproducible method suitable for clinical applications. This approach can be adapted for future CAR-T products and will support the monitoring and the management of CAR-T cell therapies.<\/jats:p>","DOI":"10.3390\/ijms25168556","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T08:07:59Z","timestamp":1722931679000},"page":"8556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-1011","authenticated-orcid":false,"given":"Gertrud","family":"Wiedemann","sequence":"first","affiliation":[{"name":"Department of Hematology and Central Hematological Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematological Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Joncourt","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematological Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Solly","sequence":"additional","affiliation":[{"name":"Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne C.","family":"Widmer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Department of Hematology, University Hospital of Basel, 4031 Basel, Switzerland"},{"name":"Laboratory Medicine, Diagnostic Hematology, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Zeerleder","sequence":"additional","affiliation":[{"name":"Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"},{"name":"Center for Hemato-Oncology, University Cancer Center, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland"},{"name":"Center for Hemato-Oncology, University Cancer Center, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2515-1935","authenticated-orcid":false,"given":"Naomi A.","family":"Porret","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematological Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"},{"name":"Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2147\/TCRM.S146309","article-title":"The Potential of CAR T Therapy for Relapsed or Refractory Pediatric and Young Adult B-Cell ALL","volume":"14","author":"Forsberg","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/HS9.0000000000000188","article-title":"CAR-T Cells: Future Perspectives","volume":"2","author":"Charrot","year":"2019","journal-title":"HemaSphere"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy-Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-Cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial Clinical Trial Updates Abstract","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR-T Cell Therapy: A Breakthrough in Traditional Cancer Treatment Strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"s3441","DOI":"10.57187\/s.3441","article-title":"Real-World Expenditures and Survival Time after CAR-T Treatment for Large B-Cell Lymphoma in Switzerland: A Retrospective Study Using Insurance Claims Data","volume":"153","author":"Trottmann","year":"2023","journal-title":"Swiss Med. Wkly."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric Antigen Receptor T Cells Persist and Induce Sustained Remissions in Relapsed Refractory Chronic Lymphocytic Leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI129208","article-title":"State of the Art in CAR T Cell Therapy for CD19+ B Cell Malignancies","volume":"130","author":"Frigault","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wittibschlager, V., Bacher, U., Seipel, K., Porret, N., Wiedemann, G., Haslebacher, C., Hoffmann, M., Daskalakis, M., Akhoundova, D., and Pabst, T. (2023). CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065688"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41409-022-01658-x","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Relapsed Mantle Cell Lymphoma: Real-World Experience from a Single Tertiary Care Center","volume":"57","author":"Heini","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hays, A., Durham, J., Gullick, B., Rudemiller, N., and Schneider, T. (2023). Bioanalytical Assay Strategies and Considerations for Measuring Cellular Kinetics. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010695"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14789450.2021.1992276","article-title":"An Overview of Multiplexed Analyses of CAR T-Cell Therapies: Insights and Potential","volume":"18","author":"DePriest","year":"2021","journal-title":"Expert Rev. Proteom."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I., and Einsele, H. (2022). Immune Monitoring. The EBMT\/EHA CAR-T Cell Handbook, Springer International Publishing.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Galli, E., Viscovo, M., Fosso, F., Pansini, I., Di Cesare, G., Iacovelli, C., Maiolo, E., Sor\u00e0, F., Hohaus, S., and Sica, S. (2024). Unlocking Predictive Power: Quantitative Assessment of CAR-T Expansion with Digital Droplet Polymerase Chain Reaction (DdPCR). Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052673"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Calder\u00f3n, C.B., Sierro-Mart\u00ednez, B., Garc\u00eda-Guerrero, E., Sanoja-Flores, L., Mu\u00f1oz-Garc\u00eda, R., Ruiz-Maldonado, V., Jimenez-Leon, M.R., Delgado-Serrano, J., Molinos-Quintana, \u00c1., and Guijarro-Albaladejo, B. (2023). Monitoring of Kinetics and Exhaustion Markers of Circulating CAR-T Cells as Early Predictive Factors in Patients with B-Cell Malignancies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1152498"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor\u2013Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1\u20132 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the Toxicities of CAR T-cell Therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor\u2013T Cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","article-title":"Analysis of IL-6 Serum Levels and CAR T Cell-Specific Digital PCR in the Context of Cytokine Release Syndrome","volume":"88","author":"Pabst","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy in Vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mika, T., Maghnouj, A., Klein-Scory, S., Ladigan-Badura, S., Baraniskin, A., Thomson, J., Hasenkamp, J., Hahn, S.A., Wulf, G., and Schroers, R. (2020). Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00084"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.transproceed.2017.11.028","article-title":"Establishment of a Quantitative Polymerase Chain Reaction Assay for Monitoring Chimeric Antigen Receptor T Cells in Peripheral Blood","volume":"50","author":"Wang","year":"2018","journal-title":"Transplant. Proc."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Badbaran, A., Berger, C., Riecken, K., Kruchen, A., Geffken, M., M\u00fcller, I., Kr\u00f6ger, N., Ayuk, F.A., and Fehse, B. (2020). Accurate In-Vivo Quantification of Cd19 Car-t Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital Pcr. Cancers, 12.","DOI":"10.3390\/cancers12071970"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.omtm.2019.12.018","article-title":"Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel","volume":"16","author":"Fehse","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., and June, C.H. (2011). T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci. Transl. Med., 3.","DOI":"10.1126\/scitranslmed.3002842"},{"key":"ref_39","unstructured":"Food and Drug Administration U.S. Food and Drug Administration Center for Biologics Evaluation and Research (2020). Long Term Follow-Up after Administration of Human Gene Therapy Products Guidance for Industry, FDA."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","article-title":"Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR","volume":"22","author":"Lou","year":"2020","journal-title":"J. Mol. Diagn."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Heini, A.D., Bacher, U., Porret, N., Wiedemann, G., Legros, M., Stalder Zeerleder, D., Seipel, K., Novak, U., Daskalakis, M., and Pabst, T. (2022). Experiences with Glofitamab Administration Following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells, 11.","DOI":"10.3390\/cells11172747"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4274\/tjh.galenos.2023.2023.0136","article-title":"Correlation of Peripheral Chimeric Antigen Receptor T-Cell (CAR-T Cell) MRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-Cell Lymphoma","volume":"40","author":"Messerli","year":"2023","journal-title":"Turk. J. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12248-021-00560-6","article-title":"Insights on Droplet Digital PCR\u2013Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy","volume":"23","author":"Sugimoto","year":"2021","journal-title":"AAPS J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal Expansion of CAR T Cells Harboring Lentivector Integration in the CBL Gene Following Anti-CD22 CAR T-Cell Therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-Targeting CAR T Cell Immunotherapy Outcomes Correlate with Genomic Modification by Vector Integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal Kinetics and Single-Cell Transcriptional Profiling of CAR-T Cells in Patients Undergoing CD19 CAR-T Immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-Targeted T Cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., ichi Matsumoto, S., Goto, A., Ugajin, M., Nakayama, M., Moriya, Y., and Hirabayashi, H. (2020). Quantitative PCR Methodology with a Volume-Based Unit for the Sophisticated Cellular Kinetic Evaluation of Chimeric Antigen Receptor T Cells. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-74927-8"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel Cellular Kinetics, Dose, and Immunogenicity in Relation to Clinical Factors in Relapsed\/Refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","article-title":"Axicabtagene Ciloleucel in Vivo Expansion and Treatment Outcome in Aggressive B-Cell Lymphoma in a Real-World Setting","volume":"5","author":"Ayuk","year":"2021","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-Cell Lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1182\/blood-2022-169212","article-title":"Monitoring the In-Vivo Expansion and Persistence of CAR-T Cells as a Tool to Help Decision Making in Patients with Aggressive B-Cell Lymphoma","volume":"140","author":"Neuchel","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A Real-World Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2144\/btn-2017-0102","article-title":"Limitations of Methods for Measuring the Concentration of Human Genomic DNA and Oligonucleotide Samples","volume":"64","author":"He","year":"2018","journal-title":"Biotechniques"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4939-7231-9_9","article-title":"Copy Number Variation Analysis by Droplet Digital PCR","volume":"1654","author":"Butcher","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of Candidate Control Genes for Diagnosis and Residual Disease Detection in Leukemic Patients Using \u201creal-Time\u201d Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RQ-PCR)\u2014A Europe against Cancer Program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:30:34Z","timestamp":1760110234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":59,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168556"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168556","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}